Nearly half of all multiple sclerosis (MS) patients who participated in clinical trials — including global, pivotal studies — had one or more comorbidities, or coexisting conditions, the most common being depression and high blood pressure, a meta-analysis study found. While the rate of patients with comorbidities “may be…

Few multiple sclerosis (MS) clinical trials have used a so-called pragmatic design, which evaluates the effectiveness of interventions in real-life routine practice, a study has found. Because such trials are better able to emulate conditions in real-world clinical practice and provide solid and more actionable evidence to inform treatment…

Advanced Innovative Partners (AIP) has agreed to assist GlobeStar Therapeutics Corporation and SMI Healthcare in designing and running clinical trials to evaluate Project Amethyst, a patented triple combination of U.S.-approved medications aiming to prevent neurodegeneration due to multiple sclerosis (MS). This definitive agreement follows a…

The rate of brain atrophy, or volume loss, may help in determining whether disease-modifying therapies (DMTs) are slowing disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a review of data from 12 published studies found. The analysis, “Brain Atrophy as an Outcome of Disease-Modifying Therapy for…

Noting that Aubagio (teriflunomide) continues to have “a robust impact on disability progression” in multiple sclerosis (MS) despite being eclipsed by newer MS treatments in trials, an international team of researchers are now arguing that it is, in fact, still ethical to use the older therapy as a…

GlobeStar Therapeutics (GSTC) is teaming up with Advanced Innovative Partners (AIP) to design and implement clinical trials of Project Amethyst, an investigational therapy for multiple sclerosis (MS) that aims to reduce neurodegeneration — when nerve cells in the body lose function and ultimately die. The new memorandum of understanding (MOU)…

The Overall Disability Response Score, a combination of three different assessments of disability, could be used to more accurately evaluate the effectiveness of treatments in multiple sclerosis (MS) clinical trials, a new study illustrates. The score is composed of three measures commonly used to assess disability in MS, which…

Stem Cell Therapy Shows 2-year Benefit for Progressive MS Patients in Phase 1 Trial Stem cell studies always catch my eye. This very small study involves people treated with their own bone marrow, which was collected and expanded to give it the ability to modulate the MS immune response…